Bronze
| Address | 64 Cheonhodaero, Dongdaemun-gu, Seoul | ||
|---|---|---|---|
| Telephone | +82-10-7635-3244 | Fax | +82-2-924-5629 |
| Website | http://www.donga-st.com/ | kyj@donga.co.kr | |
With its optimized research infrastructures such as its world-class, sophisticated research center completed in 2011, as well as its excellent researchers, Dong-A ST is furthering its efforts to develop global new drugs. Also, with the backing of these infrastructures, Dong-A ST vows to positively explore overseas markets, to expand its overseas exports, and to establish itself as a global pharmaceutical company, operating beyond the domestic market.
Leucostim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology. G-CSF regulates the production of neutrophils within the bone marrow and affects neutrophil progenitor proliferation, differentiation and enhances phagocytic activity. Leucostim is a glycoprotein which regulates the production and release of functional neutrophils from the bone marrow. Leucostim causes marked increases in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes. Elevations of neutrophil counts are dose-dependent at recommended doses. Following termination of Leucostim therapy, circulating neutrophil counts decrease by 50% within 1 to 2 days, and to normal levels within 1 to 7 days.
